Eli Lilly’s CDK 4 and 6 inhibitor Verzenios has been approved in Europe for the treatment of certain metastatic breast cancers.
News
GSK updates its HCP payment policy
GlaxoSmithKline is overturning a blanket ban on payments to doctors promoting its medicines, now allowing the practice under certain circumstances.
Digital health projects win £17 million
The government has unveiled the winning projects of the latest Digital Health Catalyst competition, which will each win a slice of £17 million handed out by the Industrial Strategy Challenge Fund to help fuel their progress.
Gov’t to unveil £240m extra social care funding
The government reportedly intends to stream an extra £240 million into social care services this winter to help alleviate pressures on the NHS.
Nobel prize awarded for research on cancer immunotherapy
US researcher James Allison and Japanese researcher Tasuku Honjo have won the 2018 Nobel Prize for Physiology or Medicine for their ground-breaking work on manipulating the immune system to combat cancer.
UK launch for Alliance’s pregnancy anti-nausea and vomiting drug
Alliance Pharma has announced the launch of Xonvea in the UK to treat nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management.
NHS England agrees to fund Janssen’s Symtuza
NHS England (NHSE) has agreed to provide funding for Janssen’s Symtuza, a once-daily darunavir-based single tablet regimen (STR), for the treatment of HIV in adults and adolescents.
US OKs Sanofi, Regeneron’s new skin cancer immunotherapy
Sanofi and Regeneron’s imunotherapy Libtayo has been cleared in the US to treat patients with certain forms of cutaneous squamous cell carcinoma (CSCC).
Shield files Feraccru with the FDA
The UK’s Shield Therapeutics has successfully submitted an application to market iron deficiency therapy Feraccru in the US.
GP closures could have ‘catastrophic’ effect on patient care, says RCGP
GP leaders are warning that more than 2.5 million patients across England could see their GP practice close in the next five years because of the high number of family doctors at risk of leaving the profession.
Lilly’s Emgality wins first nod for migraine prevention
The US Food and Drug Administration have green-lighted use of Eli Lilly’s non-opioid pain drug Emgality for the prevention of migraine.
GW Pharma’s Epidiolex nears US launch
GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified the cannabis-based medicine to the lowest restriction.
NHS England pledges £10m to support GP services over winter
NHS England says it will provide £10 million to GPs to help support delivery of additional extended hours, out of hours and unscheduled care sessions over the winter period.
US green light for Pfizer’s lung cancer drug
Pfizer’s pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib has been approved in the US as a treatment for some forms of lung cancer.
Lilly’s snaps up Chugai’s experimental diabetes drug
Lilly has entered into an agreement to develop Chugai’s OWL833, a oral non-peptidic GLP-1 receptor agonist currently in Phase I for type II diabetes.
